What is Leerink Partnrs’ Estimate for CLDX FY2024 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Leerink Partnrs cut their FY2024 EPS estimates for Celldex Therapeutics in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings of ($2.45) per share for the year, down from their previous forecast of ($2.38). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.50) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ Q4 2024 earnings at ($0.71) EPS, FY2025 earnings at ($3.22) EPS, FY2026 earnings at ($4.17) EPS and FY2027 earnings at ($4.12) EPS.

CLDX has been the subject of several other reports. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a report on Monday, September 30th. They set a “neutral” rating and a $45.00 target price for the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, November 7th. Finally, Citigroup initiated coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $26.21 on Monday. The firm has a market capitalization of $1.74 billion, a PE ratio of -10.16 and a beta of 1.60. Celldex Therapeutics has a one year low of $24.43 and a one year high of $53.18. The company has a 50-day simple moving average of $33.60 and a 200-day simple moving average of $35.79.

Institutional Trading of Celldex Therapeutics

Institutional investors have recently made changes to their positions in the stock. Swiss National Bank raised its holdings in Celldex Therapeutics by 17.8% during the first quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock worth $4,797,000 after purchasing an additional 17,300 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics in the first quarter valued at $147,000. ProShare Advisors LLC boosted its stake in Celldex Therapeutics by 45.2% during the first quarter. ProShare Advisors LLC now owns 11,166 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 3,476 shares in the last quarter. Vanguard Group Inc. grew its holdings in Celldex Therapeutics by 19.8% during the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock worth $153,215,000 after acquiring an additional 604,251 shares during the period. Finally, Ameritas Investment Partners Inc. grew its holdings in Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 1,582 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.